Gold prices set for weekly drop as dollar surges; Trump tariff action in focus
On Thursday, H.C. Wainwright analyst Mitchell S. Kapoor revised the price target on Alumis Inc (NASDAQ:ALMS) to $19.00, down from the previous target of $26.00, while retaining a Buy rating for the company’s shares. The adjustment follows the announcement made by Alumis on Wednesday about its all-stock merger with ACELYRIN. According to InvestingPro data, the stock is currently trading at $6.59, near its 52-week low of $6.29, suggesting significant upside potential to analyst targets ranging from $25 to $32.
The combined pro forma cash position of Alumis and ACELYRIN at the end of 2024 is approximately $737 million. Alumis anticipates this will fund the company’s operations and capital expenditures into 2027. The merger, slated for completion in the second quarter of 2025, will result in Alumis and ACELYRIN stockholders owning approximately 55% and 45% of the combined company, respectively. InvestingPro analysis shows Alumis maintains a strong liquidity position with a current ratio of 11.26, though the company is currently burning through cash rapidly.
Kapoor highlighted the merger as an innovative and advantageous strategy for Alumis to obtain capital. Alumis, with nearly 55 million shares outstanding, is estimated to be issuing about 45 million shares to ACELYRIN shareholders in return for roughly $448 million in cash. This capital raise equates to around $10 per share, significantly higher than Alumis’s closing share price of $7.24 the day before the merger announcement. Based on InvestingPro’s Fair Value analysis, Alumis appears undervalued at current levels, with additional financial health metrics and insights available to subscribers.
The analyst expressed optimism regarding the terms of the transaction and the financial security it provides Alumis. This is seen as a risk mitigation factor for investors ahead of the anticipated first-half 2026 Phase 3 ESK-002 data readout for psoriasis treatment. After updating their financial model to reflect the dilution from the merger and advancing the timeline, H.C. Wainwright has set a new 12-month price target of $19 per share, down from the previous estimate of $26, while reaffirming the Buy rating on Alumis stock. The company’s market capitalization currently stands at $358.54 million, with its next earnings report expected on February 26, 2025.
In other recent news, Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement in an all-stock deal. The merger aims to create a biopharmaceutical powerhouse specializing in immune-mediated diseases. The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024. The transaction is expected to close in the second quarter of 2025, subject to approval by the stockholders of both companies.
Oppenheimer has initiated coverage on Alumis Inc with an Outperform rating and a $32.00 price target. The firm has confidence in Alumis’s prospects and anticipates transformational clinical data expected in 2026. H.C. Wainwright has also reaffirmed a Buy rating and a $26.00 price target on Alumis Inc, expressing confidence in the company’s lead product candidate, ESK-001.
Alumis Inc. has also announced key executive appointments as it prepares for late-stage development and commercialization of its drug pipeline. The company has successfully completed a Phase 1 clinical trial for its drug candidate A-005, intended to treat multiple sclerosis. The results of the trial support the advancement of A-005 to a Phase 2 clinical trial for MS patients, anticipated to commence in the second half of 2025. These are the recent developments surrounding Alumis Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.